The canine atopic dermatitis treatment drugs market is estimated to be valued at US$ 1038.28 Mn in 2023 and is expected to exhibit a CAGR of 16% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.


Canine atopic dermatitis is a long-term allergic skin condition in dogs that results in severe itching, red skin, rashes, and hair loss. The condition worsens due to factors such as genetics, allergens, and secondary skin infections. Treatment drugs for atopic dermatitis include antihistamines, corticosteroids, cyclosporine, oclacitinib, and monoclonal antibodies that control inflammation and itching.

Market Dynamics:
The global canine atopic dermatitis treatment drugs market is driven by increasing pet adoption, especially in developed economies. According to the American Pet Products Association (APPA), around 23.6 Mn American families adopted dogs in 2021 indicating a 7.6% increase from 2019. Growing humanization of pets and rising awareness about animal health among owners is boosting the market growth. Furthermore, new product launches with better efficacy and fewer side effects are also supporting the market expansion. For instance, in June 2022, Kindred Biosciences, Inc. announced the commercial launch of Mirataz (mirtazapine transdermal ointment) for the management of weight loss and decreased appetite in cats. The ointment is well tolerated with fewer adverse effects than pills and protects skin health.

SWOT Analysis

Strength: The canine atopic dermatitis treatment drugs market has seen numerous product launches over the past few years. For instance, Zeotis launched the Monodoser therapy in 2021 for the treatment of atopic dermatitis in dogs. Such new product launches will strengthen the company’s product portfolio. Moreover, growing awareness among pet owners regarding various skin disorders in dogs is expected to drive the demand for effective treatment drugs.
Weakness: High costs associated with veterinary care and prescription medication can limit the demand for canine atopic dermatitis treatment drugs from budget-constrained pet owners. Moreover, the side effects associated with few drugs such as diarrhea and vomiting can negatively impact the market's growth.
Opportunity: Rising pet humanization trend and increasing spending on pets present lucrative growth opportunities. Moreover, increasing prevalence of canine atopic dermatitis cases owing to change in lifestyle and environmental conditions will augment the market expansion.
Threats: Stringent regulations pertaining to veterinary drugs approvals can substantially increase the timeline and costs related to new product development. Moreover, threat from substitute treatment options such as herbal medications and allergen-specific immunotherapy poses challenges.

Key Takeaways
The Global Canine Atopic Dermatitis Treatment Drugs Market Size is expected to witness high growth, exhibiting CAGR of 16.% over the forecast period, due to increasing pet humanization trend and growing pet healthcare expenditure. According to stats, total U.S pet industry expenditure stood at US$ 99 billion in 2020.

Regional analysis The North America region dominated the global market in 2023 and is expected to exhibit a similar trend during the forecast period. This is attributed to growing pet ownership and increasing per capita animal healthcare expenditure in the region. Moreover, presence of majority key players and frequent new product launches will support the regional market growth.

Key players
Key players operating in the canine atopic dermatitis treatment drugs market are Zeotis Inc, Elanco Animal Health Incorporated, Virbac, Kindred Biosciences, Inc., Nippon Zenyaku Kogyo Co., Ltd., Bioiberica S.A.U., Dechra Pharmaceuticals Plc, and Toray Industries, Inc. These players are focusing on new product development and commercialization to strengthen their market position. For instance, in 2022, KindredBio launched its canine atopic dermatitis antibody biologic drug KIND-030 for atopic dogs.

Get More Insights On This Topic: https://cmiresearch.blogspot.com/2023/12/canine-atopic-eczema-drugs-is-fastest.html